Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 3/20 | 0.56 |
| ▸ | KCNJ1 | P48048 | 3/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.34 |
| ▸ | TYK2 | P29597 | 2/20 | 0.34 |
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
| ▸ | PANK3 | Q9H999 | 9/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3229010 | 1.00 | SCD (0.56) | SCDKCNJ1TNKSTNKS2IDO1 | |
| SCHEMBL3222804 | 0.93 | SCD (0.48) | SCDKCNJ1TNKSTNKS2IDO1 | |
| SCHEMBL3222795 | 0.93 | SCD (0.48) | SCDKCNJ1TNKSTNKS2IDO1 | |
| SCHEMBL3226005 | 0.79 | SCD (0.57) | SCDTNKSTNKS2IDO1AVPR1A | |
| SCHEMBL3226001 | 0.79 | SCD (0.57) | SCDTNKSTNKS2IDO1AVPR1A | |
| SCHEMBL3259787 | 0.76 | SCD (0.55) | SCDTNKSTNKS2IDO1AVPR1A | |
| SCHEMBL3259786 | 0.76 | SCD (0.55) | SCDTNKSTNKS2IDO1AVPR1A | |
| SCHEMBL3227871 | 0.75 | SCD (0.54) | SCDTNKSTNKS2IDO1AVPR1A | |
| SCHEMBL3227873 | 0.75 | SCD (0.54) | SCDTNKSTNKS2IDO1AVPR1A | |
| SCHEMBL3232181 | 0.74 | SCD (0.75) | SCDTNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575167-B2 | Spiro compounds having stearoyl-CoA desaturase action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | SCD, SPR, SCD5 | SCD 1/4885KCNJ1 1855/4885TNKS 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.